WESTERN-UNION-COMPANY
17.9.2020 15:02:34 CEST | Business Wire | Press release
Western Union, a leader in cross-border, cross-currency money movement and payments, announces a collaboration between its business division, Western Union Business Solutions , and Isabel Group , the leading provider of multi-bank services for both businesses and consumers and largest Fintech in Belgium.
As part of its partnership, Western Union Business Solutions will provide worldwide connectivity to Isabel Group’s multi-banking platform that enables organizations to manage their banking online and perform quick and easy payments. The Isabel 6 platform serves 70,000 professional user clients, and now collectively may access Western Union Business Solutions’ unrivaled global payment network across over 200 countries and territories in more than 130 currencies around the world. Western Union Business Solutions’ extensive global network, combined with knowledge of local markets, will help enable Isabel platform users to manage international payments simply, effectively, and efficiently. The expertise of Western Union Business Solutions’ foreign exchange specialists on currency fluctuation and foreign exchange markets will assist clients in managing international payments and foreign exchange risk through a wide range of hedging product offering.
Marc-Elie Caspar, country director France & Benelux at Western Union Business Solutions, notes:
“We are proud to extend and accelerate our presence and activities in Belgium through this key partnership with Isabel Group, the largest Fintech player offering the most popular B2B multi-banking ecosystem and online payment solution for companies of any size in Belgium. Together, we will offer our customers an innovative payment solution for foreign exchange transactions, dedicated customer support, negotiated rates and fees and an outstanding level of trust thanks to our European banking license.
“This type of partnership is part of our DNA at Western Union Business Solutions. We equip and support organizations around the world that are looking for a partner to optimize cross-border payments with solutions for sending, receiving, and managing international payments.”
The Isabel 6 platform is backed by the expertise, resources and technology provided by Isabel Group. The Belgian fintech has an extensive network of partners and is one of the three companies in Belgium (source: AMPG) to meet the requirements of the ISO/IEC 20000-1 2011 standard and to have obtained the certification corresponding to this standard.
Jean de Crane, CEO at Isabel Group, adds: “We are happy to welcome Western Union Business Solutions as a new international member on the Isabel 6 multi-banking platform. This collaboration will add value to our mutual business customers in the processing of their payments and foreign exchange strategies. We are looking forward to working together with this international player in our ecosystem.”
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .
About Isabel Group
Isabel Group links and streamlines the administrative and financial processes of businesses. The financial services provider ensures a smooth and reliable exchange of documents, payments, and identities, and automates access to them. This helps businesses to gain insight into their financial flows and make better business decisions.
Some 65,000 businesses, 3,000 accounting firms, 150 software partners, and 30 banks are working with or linked to Isabel Group’s software: Isabel 6, Seven, Ibanity, CodaBox, ClearFacts, Ponto, BookMate, SignHere, KUBE and Zoomit. This means that Isabel Group is managing Belgium’s most extensive financial infrastructure. With more than 300 experts, the group automates 450 million transactions per year or 7.10 billion euros per day.
WU-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005169/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom